{"protocolSection":{"identificationModule":{"nctId":"NCT01859143","orgStudyIdInfo":{"id":"MED-VA-FLUMIST-1156"},"organization":{"fullName":"MedImmune LLC","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults"},"statusModule":{"statusVerifiedDate":"2014-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-05"},"primaryCompletionDateStruct":{"date":"2013-12","type":"ACTUAL"},"completionDateStruct":{"date":"2013-12","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-17","studyFirstSubmitQcDate":"2013-05-20","studyFirstPostDateStruct":{"date":"2013-05-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-30","resultsFirstSubmitQcDate":"2014-11-07","resultsFirstPostDateStruct":{"date":"2014-11-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-11-07","lastUpdatePostDateStruct":{"date":"2014-11-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MedImmune LLC","class":"INDUSTRY"},"collaborators":[{"name":"AstraZeneca","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This prospective annual release study is designed to evaluate the safety on new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2013-2014 influenza season.","detailedDescription":"This prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site. This study will be conducted at 3 sites in the United States of America. Each subject will receive 1 dose of investigational product on Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination."},"conditionsModule":{"conditions":["Influenza","Healthy"],"keywords":["Trivalent","Influenza","FluMist Quadrivalent","Vaccine","Prevention","Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":300,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Trivalent Influenza Vaccine","type":"EXPERIMENTAL","description":"A single dose of 10\\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.","interventionNames":["Biological: Trivalent Influenza Vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.","armGroupLabels":["Trivalent Influenza Vaccine"]},{"type":"OTHER","name":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)","description":"Percentage of participants with fever defined as oral temperature \\>=101 degrees F were reported.","timeFrame":"Within 7 days after vaccination"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Solicited Symptoms","description":"Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily after vaccine administration up to 14 days after vaccination. The solicited symptoms included fever greater than (\\>) 100.0 degrees F (37.8 degrees Celsius), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity and headache. Results are reported for all solicited symptoms except fever \\>=101 degrees F (reported as primary outcome) within 7 days after vaccination and all solicited symptoms within 14 days after vaccination.","timeFrame":"Within 7 and 14 days after vaccination"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events between administration of study drug and up to 14 days after vaccination that were absent before treatment or that worsened relative to pre-treatment state. Results are given for AEs reported within 7 days and 14 days after vaccination.","timeFrame":"Within 7 and 14 days after vaccination"},{"measure":"Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)","description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent SAEs were serious events between administration of study drug and up to 180 days after the dose that were absent before treatment or that worsen relative to pretreatment state. An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Results are given for TESAEs and NOCDs reported within 28 days and 180 days after vaccination.","timeFrame":"Within 28 and 180 days after vaccination"},{"measure":"Percentage of Participants Who Required Antipyretic and/or Analgesic Medication","timeFrame":"Within 7 and 14 days after vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 through 49 years\n* Written informed consent\n* Subject available by telephone\n* Ability to understand and comply with the requirements of the protocol, as judged by the Investigator\n\nExclusion Criteria:\n\n* Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)\n* History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations\n* Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (example \\[eg\\], asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year\n* Acute febrile (greater than \\[\\>\\] 100.0 degrees Fahrenheit \\[F\\] oral or equivalent) and/or clinically significant respiratory illness (example, cough or sore throat) within 14 days prior to randomization\n* Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy\n* History of Guillain-Barré syndrome","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Raburn Mallory, MD","affiliation":"MedImmune LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Stockbridge","state":"Georgia","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Research Site","city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"One participant randomized to receive placebo received trivalent influenza vaccine on Day 1 instead of placebo and was included in trivalent influenza vaccine group in the safety population.","groups":[{"id":"FG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"FG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"240"},{"groupId":"FG001","comment":"One participant in this group received trivalent influenza vaccine on Day 1.","numSubjects":"60"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"238"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis population included all randomized participants.","groups":[{"id":"BG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"BG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"240"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"300"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33.1","spread":"9.4"},{"groupId":"BG001","value":"33.6","spread":"9.0"},{"groupId":"BG002","value":"33.2","spread":"9.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"137"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"171"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"129"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F)","description":"Percentage of participants with fever defined as oral temperature \\>=101 degrees F were reported.","populationDescription":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Within 7 days after vaccination","groups":[{"id":"OG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"Pre-specified equivalence criterion for fever within 7 days of vaccination mentioned that the upper limit of 95 percent (%) confidence interval (CI) for difference in percentage of participants with fever \\>=101 degrees F should be less than 5 percentage points.","paramType":"Percent difference","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.3","ciUpperLimit":"2.6","estimateComment":"A two-sided 95% CI was constructed using the exact method based on the score statistic proposed by Chan and Zhang."}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Symptoms","description":"Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily after vaccine administration up to 14 days after vaccination. The solicited symptoms included fever greater than (\\>) 100.0 degrees F (37.8 degrees Celsius), runny nose, sore throat, cough, vomiting, muscle aches, chills, decreased activity and headache. Results are reported for all solicited symptoms except fever \\>=101 degrees F (reported as primary outcome) within 7 days after vaccination and all solicited symptoms within 14 days after vaccination.","populationDescription":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Within 7 and 14 days after vaccination","groups":[{"id":"OG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) FFU of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Any symptom within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"37.3"},{"groupId":"OG001","value":"25.4"}]}]},{"title":"Fever: greater than 100 degrees F within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever: greater than 102 degrees F within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever: greater than 103 degrees F within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Runny nose within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"20.7"},{"groupId":"OG001","value":"11.9"}]}]},{"title":"Sore throat within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"3.4"}]}]},{"title":"Cough within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"4.6"},{"groupId":"OG001","value":"5.1"}]}]},{"title":"Vomiting within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Muscle aches within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"3.4"}]}]},{"title":"Chills within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Decreased activity (tiredness) within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"10.0"},{"groupId":"OG001","value":"6.8"}]}]},{"title":"Headache within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"15.4"},{"groupId":"OG001","value":"11.9"}]}]},{"title":"Any symptom within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"39.4"},{"groupId":"OG001","value":"27.1"}]}]},{"title":"Fever: greater than 100 degrees F within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever: >= 101 degrees F within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever: greater than 102 degrees F within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever: greater than 103 degrees F within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Runny nose within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"21.6"},{"groupId":"OG001","value":"11.9"}]}]},{"title":"Sore throat within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"11.2"},{"groupId":"OG001","value":"6.8"}]}]},{"title":"Cough within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"5.1"}]}]},{"title":"Vomiting within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"0.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Muscle aches within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"3.4"}]}]},{"title":"Chills within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Decreased activity (tiredness) within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"11.2"},{"groupId":"OG001","value":"6.8"}]}]},{"title":"Headache within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"16.6"},{"groupId":"OG001","value":"13.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"11.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.9","ciUpperLimit":"23.9","estimateComment":"Any symptom within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.9","ciUpperLimit":"3.3","estimateComment":"Fever \\>100 degrees F within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.1","ciUpperLimit":"1.8","estimateComment":"Fever \\>102 degrees F within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.1","ciUpperLimit":"1.8","estimateComment":"Fever \\>103 degrees F within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"8.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.6","ciUpperLimit":"17.7","estimateComment":"Runny nose within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"6.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"11.6","estimateComment":"Sore throat within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.3","ciUpperLimit":"4.7","estimateComment":"Cough within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.1","ciUpperLimit":"1.8","estimateComment":"Vomiting within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.0","ciUpperLimit":"4.3","estimateComment":"Muscle aches within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"1.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.1","ciUpperLimit":"4.4","estimateComment":"Chills within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"3.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.5","ciUpperLimit":"9.8","estimateComment":"Decreased activity (tiredness) within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"3.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.8","ciUpperLimit":"11.9","estimateComment":"Headache within 7 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"12.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"24.4","estimateComment":"Any symptom within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.5","ciUpperLimit":"3.9","estimateComment":"Fever \\>100 degrees F within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.9","ciUpperLimit":"3.3","estimateComment":"Fever \\>=101 degrees F within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.1","ciUpperLimit":"1.8","estimateComment":"Fever \\>102 degrees F within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.1","ciUpperLimit":"1.8","estimateComment":"Fever \\>103 degrees F within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"9.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.8","ciUpperLimit":"18.6","estimateComment":"Runny nose within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.3","ciUpperLimit":"11.2","estimateComment":"Sore throat within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.6","ciUpperLimit":"5.7","estimateComment":"Cough within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.3","ciUpperLimit":"2.6","estimateComment":"Vomiting within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.8","ciUpperLimit":"4.8","estimateComment":"Muscle aches within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"2.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.3","ciUpperLimit":"5.5","estimateComment":"Chills within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"4.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.3","ciUpperLimit":"11.2","estimateComment":"Decreased activity (tiredness) within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Percent difference","paramValue":"3.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.7","ciUpperLimit":"12.0","estimateComment":"Headache within 14 days of vaccination: Difference in percentage of participants and 95% CI were constructed based on Chan and Zhang's method."}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were events between administration of study drug and up to 14 days after vaccination that were absent before treatment or that worsened relative to pre-treatment state. Results are given for AEs reported within 7 days and 14 days after vaccination.","populationDescription":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Within 7 and 14 days after vaccination","groups":[{"id":"OG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) FFU of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"4"}]}]},{"title":"Within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and New Onset Chronic Diseases (NOCDs)","description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent SAEs were serious events between administration of study drug and up to 180 days after the dose that were absent before treatment or that worsen relative to pretreatment state. An NOCD was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Results are given for TESAEs and NOCDs reported within 28 days and 180 days after vaccination.","populationDescription":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Within 28 and 180 days after vaccination","groups":[{"id":"OG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) FFU of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"TESAEs within 28 days","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"TESAEs within 180 days","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"NOCDs within 28 days","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"NOCDs within 180 days","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required Antipyretic and/or Analgesic Medication","populationDescription":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Within 7 and 14 days after vaccination","groups":[{"id":"OG000","title":"Trivalent Influenza Vaccine","description":"A single dose of 10\\^(7.0 +/- 0.5) FFU of trivalent influenza vaccine administered as intranasal spray on Day 1."},{"id":"OG001","title":"Placebo","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Anti-pyretic or analgesic within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"5.1"}]}]},{"title":"Anti-pyretic and analgesic within 7 days","categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"5.1"}]}]},{"title":"Anti-pyretic or analgesic within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"6.8"}]}]},{"title":"Anti-pyretic and analgesic within 14 days","categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"6.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Serious Adverse events (SAEs): up to 180 days after vaccination; other adverse events (AEs): up to 14 days after vaccination","description":"Safety population included all participants who received any amount of investigational drug and had safety data available. Participants were included in the safety population according to the investigational drug received.","eventGroups":[{"id":"EG000","title":"TRIVALENT VACCINE","description":"A single dose of 10\\^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine administered as intranasal spray on Day 1.","seriousNumAffected":1,"seriousNumAtRisk":241,"otherNumAffected":28,"otherNumAtRisk":241},{"id":"EG001","title":"PLACEBO","description":"A single dose of placebo matched to trivalent influenza vaccine administered as intranasal spray on Day 1.","seriousNumAffected":2,"seriousNumAtRisk":59,"otherNumAffected":5,"otherNumAtRisk":59}],"seriousEvents":[{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Menorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]}],"otherEvents":[{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Acute tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":241},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59}]},{"term":"Nasal discharge discolouration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":241},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":59}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":241},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication."},"pointOfContact":{"title":"Raburn Mallory, MD/Senior Director, Clinical Development","organization":"MedImmune, LLC","email":"malloryr@medimmune.com","phone":"301-398-0000"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D007252","term":"Influenza Vaccines"}],"ancestors":[{"id":"D014765","term":"Viral Vaccines"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"}]}},"hasResults":true}